Back to search

Netherlands· NL-a7451ffc015a

Ordspono 2 mg concentraat voor oplossing voor infusie

A odronextamab product containing odronextamab, registered in Netherlands by Regeneron Ireland Designated Activity Company. The same ATC class is registered in 6 of our 19 countries.

ATC L01FX34

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOrdspono 2 mg concentraat voor oploss…ATCL01FX34REGISTER NO.NL-a7451ffc015aPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Odronextamab is registered in 6 of 19 countries.

Countries holding a registration under ATC L01FX34 (odronextamab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 3 of them publish a price we can compare per daily dose

Odronextamab · ATC L01FX34

6 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ODRONEXTAMAB
Manufacturer
Regeneron Ireland Designated Activity Company
Country
Netherlands (NL)
ATC code
L01FX34
ATC class
Odronextamab
Defined daily dose
12.86 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/24/1843

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/34ab45aa-d329-429c-a4e7-cf3f86df695e
GET /v1/drugs/34ab45aa-d329-429c-a4e7-cf3f86df695e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ordspono-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Odronextamab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131968",
  "excipients": [
    "HISTIDINE, (L-)",
    "HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
    "POLYSORBAAT 80 (E 433)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "ODRONEXTAMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/08/22",
  "procedure_number": "EMEA/H/C/006215",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1843",
  "additional_monitoring": "Y"
}

See everything about odronextamab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.